Treatment Outcomes of Helical Intensity-Modulated Radiotherapy for  Unresectable Hepatocellular Carcinoma

공문규; 홍성언; 최우석; 최진현; 김영경

추천

검색

자료유형: 학술저널

저자정보: 공문규 홍성언 최우석 최진현 김영경

저널정보: 거트앤리버 발행위원회 Gut and Liver Gut and Liver 제7권 제3호

발행연도: 2013.1

수록면: 343 - 351 (9page)

이용수

📌

연구주제

📖

연구배경

🔬

연구방법

🏆

연구결과

초록· 키워드

오류제보하기

Background/Aims: This study reports treatment outcomes after helical intensity-modulated radiotherapy (IMRT) in unresectable hepatocellular carcinoma (HCC) patients for whom transarterial chemoembolization (TACE) was considered ineffective or unsuitable. Methods: From January 2008 to December 2011, 22 unresectable HCC patients received helical IMRT. A daily dose of 1.8 to 4 Gy was delivered at five fractions per week to deliver a total dose of 30 to 60 Gy. The most-prescribed dose fractionation was a total dose of 50 to 57.5 Gy, with a daily dose of 2.3 to 2.5 Gy. Results: In the entire group, the objective response rate of the primary tumor was 72.7%. In the eight patients with portal vein thrombosis (PVT), the objective response rate of PVT was 50.0%. Median disease progression-free survival was 11.8 months, and the 1-year disease progression-free survival rate was 40.2%. The median overall survival was 14.4 months, and the 1- and 2-year overall survival rates were 86.4% and 69.1%, respectively. PVT and Child-Pugh classifications were significant prognostic factors for overall survival in multivariate analyses. Conclusions: Helical IMRT in patients with unresectable HCC resulted in high treatment response and survival rates. This study suggests helical IMRT is a practical treatment option for HCC patients in whom TACE is unsuitable or ineffective.

#Helical intensity-modulated radiotherapy #Hepatocellular carcinoma #Objective response rate #Prognostic factor #Survival rate

참고문헌 (21)

참고문헌 신청

Cheng AL / 2009 / Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placeb

Cheng SH / 1999 / A pilot study of three-dimensional conformal radiotherapy in unresectable hepatocellular carcinoma / J Gastroenterol Hepatol 14 : 1025 ~ 1033

Eisenhauer EA / 2009 / New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1) / Eur J Cancer 45 : 228 ~ 247

Fowler JF / 1989 / The linear-quadratic formula and progress in fractionated radiotherapy / Br J Radiol 62 : 679 ~ 694

Guo WJ / 2000 / Evaluation of combined therapy with chemoembolization and irradiation for large hepatocellular carcinoma / Br J Radiol 73 : 1091 ~ 1097